Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$44.86 USD
-0.20 (-0.44%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $44.83 -0.03 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
by Zacks Equity Research
Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -24.43% and 5.20%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Ultragenyx (RARE) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Begins Dosing in Pivotal Study on Setrusumab
by Zacks Equity Research
Ultragenyx (RARE) doses the first patient in a pivotal phase II/III study evaluating setrusumab (UX143) for the treatment of osteogenesis imperfecta.
Ultragenyx's (RARE) Q4 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the fourth quarter of 2021 while revenues miss estimates.
Ultragenyx (RARE) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -35.61% and 0.69%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Collaborates With Ultragenyx for Evkeeza
by Zacks Equity Research
Regeneron (REGN) teams up with Ultragenyx Pharmaceutical to commercialize and distribute Evkeeza (evinacumab) outside the United States.
Why Is Ultragenyx (RARE) Down 11.4% Since Last Earnings Report?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ultragenyx (RARE) Begins Dosing in Phase I/II Study of UX053
by Zacks Equity Research
Ultragenyx (RARE) doses the first patient in a phase I/II study evaluating its investigational mRNA candidate, UX053, for treating glycogen storage disease type III.
Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.
Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of 24.48% and 4.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ultragenyx (RARE) Q3 Earnings Expected to Decline
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ultragenyx (RARE) Begins Angelman Syndrome Study in Canada
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics dose the first patient in a phase I/II study on GTX-102 for treating patients with Angelman syndrome in Canada.
Ultragenyx (RARE) Reports FDA Removal of Clinical Hold on Study
by Zacks Equity Research
Ultragenyx (RARE) and GeneTx Biotherapeutics to start dosing in the phase I/II study on GTX-102 for treating pediatric patients with Angelman syndrome after the FDA removes its clinical hold on the same.
Ultragenyx (RARE) Up 15% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Gets Fast Track Tag for Wilson Disease Candidate
by Zacks Equity Research
The FDA bestows a Fast Track designation to Pfizer (PFE) and partner Vivet Therapeutics' clinical-stage gene therapy, VTX-801, for the treatment of Wilson disease.
Ultragenyx (RARE) Q2 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical's (RARE) Q2 sales increase year over year while loss widens.
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -13.28% and 4.28%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ultragenyx (RARE) Q2 Earnings Expected to Decline
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for June 18th
by Zacks Equity Research
OEG, EAF, RARE, EGRX, and TELA have been added to the Zacks Rank #5 (Strong Sell) List on June 18, 2021
Ultragenyx (RARE) Down 7.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for May 10th
by Zacks Equity Research
RARE, MCFE, LDI, INTZ, and DHX have been added to the Zacks Rank #5 (Strong Sell) List on May 10, 2021
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows